vs
百利高（PRGO）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Rollins, Inc.的1.2倍（$1.1B vs $906.4M），Rollins, Inc.净利率更高（11.9% vs -127.8%，领先139.7%），Rollins, Inc.同比增速更快（10.2% vs -2.5%），百利高自由现金流更多（$148.6M vs $111.2M），过去两年百利高的营收复合增速更高（1.3% vs 0.8%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
PRGO vs ROL — 直观对比
营收规模更大
PRGO
是对方的1.2倍
$906.4M
营收增速更快
ROL
高出12.7%
-2.5%
净利率更高
ROL
高出139.7%
-127.8%
自由现金流更多
PRGO
多$37.4M
$111.2M
两年增速更快
PRGO
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $906.4M |
| 净利润 | $-1.4B | $107.8M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | 16.1% |
| 净利率 | -127.8% | 11.9% |
| 营收同比 | -2.5% | 10.2% |
| 净利润同比 | -3093.9% | 2.5% |
| 每股收益（稀释后） | $-10.23 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.1B | $912.9M | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.1B | $999.5M | ||
| Q1 25 | $1.0B | $822.5M | ||
| Q4 24 | $1.1B | $832.2M | ||
| Q3 24 | $1.1B | $916.3M | ||
| Q2 24 | $1.1B | $891.9M |
净利润PRGOROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-1.4B | $116.4M | ||
| Q3 25 | $7.5M | $163.5M | ||
| Q2 25 | $-8.4M | $141.5M | ||
| Q1 25 | $-6.4M | $105.2M | ||
| Q4 24 | $-44.4M | $105.7M | ||
| Q3 24 | $-21.0M | $136.9M | ||
| Q2 24 | $-108.4M | $129.4M |
毛利率PRGOROL
| Q1 26 | — | — | ||
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — |
营业利润率PRGOROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | -116.0% | 17.5% | ||
| Q3 25 | 7.0% | 21.9% | ||
| Q2 25 | 4.3% | 19.8% | ||
| Q1 25 | 4.5% | 17.3% | ||
| Q4 24 | 10.0% | 18.1% | ||
| Q3 24 | 7.4% | 20.9% | ||
| Q2 24 | -2.5% | 20.4% |
净利率PRGOROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -127.8% | 12.8% | ||
| Q3 25 | 0.7% | 15.9% | ||
| Q2 25 | -0.8% | 14.2% | ||
| Q1 25 | -0.6% | 12.8% | ||
| Q4 24 | -3.9% | 12.7% | ||
| Q3 24 | -1.9% | 14.9% | ||
| Q2 24 | -10.2% | 14.5% |
每股收益（稀释后）PRGOROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-10.23 | $0.24 | ||
| Q3 25 | $0.05 | $0.34 | ||
| Q2 25 | $-0.06 | $0.29 | ||
| Q1 25 | $-0.05 | $0.22 | ||
| Q4 24 | $-0.32 | $0.22 | ||
| Q3 24 | $-0.15 | $0.28 | ||
| Q2 24 | $-0.79 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $2.9B | $1.4B |
| 总资产 | $8.5B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资PRGOROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | $432.1M | $127.4M | ||
| Q2 25 | $454.2M | $123.0M | ||
| Q1 25 | $409.9M | $201.2M | ||
| Q4 24 | $558.8M | $89.6M | ||
| Q3 24 | $1.5B | $95.3M | ||
| Q2 24 | $542.8M | $106.7M |
总债务PRGOROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PRGOROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.9B | $1.4B | ||
| Q3 25 | $4.4B | $1.5B | ||
| Q2 25 | $4.5B | $1.4B | ||
| Q1 25 | $4.4B | $1.4B | ||
| Q4 24 | $4.3B | $1.3B | ||
| Q3 24 | $4.6B | $1.3B | ||
| Q2 24 | $4.5B | $1.2B |
总资产PRGOROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $8.5B | $3.1B | ||
| Q3 25 | $10.1B | $3.2B | ||
| Q2 25 | $10.1B | $3.2B | ||
| Q1 25 | $9.8B | $2.9B | ||
| Q4 24 | $9.6B | $2.8B | ||
| Q3 24 | $11.2B | $2.8B | ||
| Q2 24 | $10.4B | $2.8B |
负债/权益比PRGOROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $111.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 12.3% |
| 资本支出强度资本支出/营收 | 2.4% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $621.1M |
8季度趋势，按日历期对齐
经营现金流PRGOROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $175.4M | $164.7M | ||
| Q3 25 | $51.7M | $191.3M | ||
| Q2 25 | $75.9M | $175.1M | ||
| Q1 25 | $-64.5M | $146.9M | ||
| Q4 24 | $312.6M | $188.2M | ||
| Q3 24 | $42.2M | $146.9M | ||
| Q2 24 | $9.5M | $145.1M |
自由现金流PRGOROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $148.6M | $159.0M | ||
| Q3 25 | $29.8M | $182.8M | ||
| Q2 25 | $56.7M | $168.0M | ||
| Q1 25 | $-90.0M | $140.1M | ||
| Q4 24 | $274.9M | $184.0M | ||
| Q3 24 | $15.1M | $139.4M | ||
| Q2 24 | $-18.9M | $136.4M |
自由现金流率PRGOROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 13.4% | 17.4% | ||
| Q3 25 | 2.9% | 17.8% | ||
| Q2 25 | 5.4% | 16.8% | ||
| Q1 25 | -8.6% | 17.0% | ||
| Q4 24 | 24.2% | 22.1% | ||
| Q3 24 | 1.4% | 15.2% | ||
| Q2 24 | -1.8% | 15.3% |
资本支出强度PRGOROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.4% | 0.6% | ||
| Q3 25 | 2.1% | 0.8% | ||
| Q2 25 | 1.8% | 0.7% | ||
| Q1 25 | 2.4% | 0.8% | ||
| Q4 24 | 3.3% | 0.5% | ||
| Q3 24 | 2.5% | 0.8% | ||
| Q2 24 | 2.7% | 1.0% |
现金转化率PRGOROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | 6.89× | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
ROL
暂无分部数据
